Drug Trial Radar · NCT03262012
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
Last checked: Nov 19, 2026Latest source record: May 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Aug 9, 2016
Primary completion
Jun 15, 2018
Study completion Jun 15, 2018
Sponsor
- Lead sponsor
- Pearl Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-Center Long-term Extension Study to Assess the Safety and Efficacy in Japanese Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) compared with Symbicort® Turbohaler®
Conditions
- COPD
Interventions
BGF MDI (PT010)Drug
Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
GFF MDI (PT003)Drug
Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
BFF MDI (PT009)Drug
Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
Symbicort® Turbohaler® Inhalation PowderDrug
Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Post-baseline Newly Occurring or Worsening PCS (Potentially Clinically Significant) Clinical Chemistry ValuesTime frame: 28 Weeks
- Incidence of Post-baseline Newly Occurring or Worsening PCS Vital SignsTime frame: 28 Weeks
- Incidence of Post-baseline Newly Occurring or Worsening PCS ECG ValuesTime frame: 28 Weeks
Locations
79 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Bunkyō City, Japan
Research Site
Chūōku, Japan
Research Site
Chūōku, Japan
Research Site
Chūōku, Japan
Research Site
Date-gun, Japan
Research Site
Fukuoka, Japan
Research Site
Ginowan-shi, Japan
Research Site
Hakata-shi, Japan
Research Site
Hamamatsu, Japan
Research Site
Hamamatsu, Japan
Research Site
Hamamatsu, Japan
Research Site
Higashiokitama-gun, Japan
Research Site
Higashiosaka-shi, Japan
Research Site
Himeji-shi, Japan
Research Site
Hirakata-shi, Japan
Research Site
Iizuka-shi, Japan
Research Site
Iwata-shi, Japan
Research Site
Izumo-shi, Japan
Research Site
Izumo-shi, Japan
Research Site
Kagoshima, Japan
Research Site
Kahoku-gun, Japan
Research Site
Kakogawa-shi, Japan
Research Site
Kasaoka-shi, Japan
Research Site
Kasuga-shi, Japan
Research Site
Kishiwada-shi, Japan
Research Site
Kiyose-shi, Japan
Research Site
Kobe, Japan
Research Site
Koga-shi, Japan
Research Site
Kurashiki-shi, Japan
Research Site
Kure-shi, Japan
Research Site
Kure-shi, Japan
Research Site
Kyoto, Japan
Research Site
Kyoto, Japan
Research Site
Kyoto, Japan
Research Site
Kyoto, Japan
Research Site
Kyoto, Japan
Research Site
Maebashi, Japan
Research Site
Matsumoto-shi, Japan
Research Site
Matsusaka-shi, Japan
Research Site
Meguro-ku, Japan
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.